Lacosamide adjunctive therapy

Lacosamide is approved as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with... 

In August 2008, lacosamide was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008 [129 ]. It is also effective against neuropathic pain attributed to distal diabetic neuropathy [130 ]. It is available as oral or intravenous formulations. 

Ben-Menachem E, Biton V, Jatuzis D, Abou-Khahl B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial onset seizures. Epilepsia 2007 48(7) 1308-17. 

Harris JA, Murphy JA. Lacosamide an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009 43(11) 1809-17. 

---

See also in sourсe #XX -- [ ]

---